Advertisement
Australia markets closed

  • ALL ORDS

    8,015.80
    +72.20 (+0.91%)
     

  • AUD/USD

    0.6641
    +0.0028 (+0.42%)
     

  • ASX 200

    7,778.10
    +77.80 (+1.01%)
     

  • OIL

    80.56
    +0.23 (+0.29%)
     

  • GOLD

    2,331.80
    +2.80 (+0.12%)
     

  • Bitcoin AUD

    97,453.61
    -1,106.09 (-1.12%)
     

  • CMC Crypto 200

    1,348.82
    -40.59 (-2.92%)
     

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Business Wire
·2-min read

BEDFORD, Mass., June 03, 2024--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences:

Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 4:00 p.m. ET

TD Cowen Genetic Medicines & RNA Summit
Date: Thursday, June 20, 2024
Time: 10:00 a.m. ET

Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/.

ADVERTISEMENT

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240603791457/en/

Contacts

Stoke Investor Contact:
Eric Rojas
Vice President, Investor Relations
IR@stoketherapeutics.com
617-312-2754